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ABSTRACT Although an elevation in myoplasmic Ca2 can activate the skeletal muscle ryanodine receptor (RyR1), the
function of this Ca2 activation is unclear because extracellular Ca2 influx is unnecessary for skeletal-type EC coupling. To
determine whether Ca2 activation of RyR1 is necessary for the initiation of skeletal-type EC coupling, we examined the
behavior of RyR1 with glutamate 4032 mutated to alanine (E4032A-RyR1) because this mutation had been shown to
dramatically reduce activation by Ca2. Proc. Natl. Acad. Sci. USA. 98:2865–2870). Analysis after reconstitution into planar
lipid bilayers revealed that E4032A-RyR1 was negligibly activated by 100 M Ca2 (Po too low to be measured). Even in the
presence of both 2 mM caffeine and 2 mM ATP, Po remained low for E4032A-RyR1 (ranging from 0.0001 in 100 M free
Ca2 to 0.005 in 2 mM free Ca2). Thus, the E4032A mutation caused a nearly complete suppression of activation of RyR1
by Ca2. Depolarization of E4032A-RyR1-expressing myotubes elicited L-type Ca2 currents of approximately normal size
and myoplasmic Ca2 transients that were skeletal-type, but about fivefold smaller than those for wild-type RyR1. The
reduced amplitude of the Ca2 transient is consistent either with the possibility that Ca2 activation amplifies Ca2 release
during EC coupling, or that the E4032A mutation generally inhibits activation of RyR1. In either case, Ca2 activation of RyR1
does not appear to be necessary for the initiation of Ca2 release during EC coupling in skeletal muscle.
INTRODUCTION
Ryanodine receptors are intracellular Ca2 release chan-
nels, currently known to be encoded in mammals by three
distinct genes. RyR1 and RyR2 are the predominant forms
in skeletal muscle and cardiac muscle, respectively
(Takeshima et al., 1989; Zorzato et al., 1990; Nakai et al.,
1990), and RyR3 is ubiquitously expressed (Hakamata et
al., 1992; Giannini et al., 1992). All three isoforms can be
activated by an elevation in cytoplasmic Ca2. In cardiac
muscle, activation of RyR2 by cytoplasmic Ca2 plays a
major role in excitation-contraction (EC) coupling. Specif-
ically, depolarization of cardiac muscle cells activates a
voltage-gated L-type Ca2 channel, which contains 1C as
its principal subunit; the resulting influx of Ca2 provides
an increase in cytoplasmic Ca2 sufficient for activating
RyR2 to release Ca2 from the sarcoplasmic reticulum
(Fabiato, 1985; Nabauer et al., 1989). An elevation of
intracellular Ca2 can also serve to activate RyR1, but the
role of this pathway is uncertain. Thus, even though skeletal
muscle expresses large numbers of L-type Ca2 channels
(containing 1S as the principle subunit), EC coupling in
skeletal muscle persists after Ca2 influx through 1S is
blocked by removal of extracellular Ca2 (Armstrong et al.,
1972) or by channel blockers (Gonzalez-Serratos et al.,
1982). Therefore, a mechanical interaction with 1S may be
responsible for the initial activation of RyR1 during “skel-
etal-type” EC coupling (Rios and Brum, 1987; Tanabe et al.,
1990) and the role of Ca2-activation during this initial
triggering of RyR1 remains unclear (e.g., Lamb et al.,
2001).
Recently, it has been reported that a glutamate conserved
in all three RyR isoforms has an important role in Ca2
activation. Specifically, mutation of this glutamate to ala-
nine in RyR2 (E3987A) and in RyR3 (E3885A) caused a
1,000–10,000-fold increase in the EC50 for activation by
Ca2, as measured by recordings of channels reconstituted
into bilayers (Chen et al., 1998; Li and Chen, 2001). The
corresponding mutation (E4032A) in RyR1 also inhibits
activation by Ca2 (Fessenden et al., 2001). Here, we have
used expression in dyspedic mouse myotubes, which lack
endogenous RyR1 (Takeshima et al., 1994; Buck et al.,
1997), to compare the effects of the E4032A mutation on
the activation by Ca2 of single RyR channels reconstituted
into planar lipid bilayers and the activation of intracellular
Ca2 release by depolarization of myotubes via the whole-
cell technique. We found that the E4032A mutation causes
100-fold suppression of RyR1 activity in bilayers in re-
sponse to Ca2, but only an 5-fold reduction in depolar-
ization-induced Ca2 release in myotubes. This residual
Ca2 release occurred via skeletal-type coupling because it
showed a sigmoidal dependence on test potential and per-
sisted after the block of Ca2 influx via L-type Ca2 cur-
rent. Thus, Ca2 activation of RyR1 does not appear to be
essential for the initiation of skeletal-type EC coupling,
although it might be important for the overall functioning of
EC coupling. In agreement with Avila et al. (2001), retro-
grade signaling, whereby RyR1 increases the L-type Ca2
Submitted October 18, 2001, and accepted for publication January 7,
2002.
Address reprint requests to Dr. Kurt G. Beam, Dept. of Anatomy and
Neurobiology, Colorado State University, Fort Collins, CO 80523. Tel.:
970-491-1566; Fax: 970-491-7907; E-mail: kbeam@lamar.colostate.edu.
© 2002 by the Biophysical Society
0006-3495/02/05/2428/08 $2.00
2428 Biophysical Journal Volume 82 May 2002 2428–2435
current carried by 1S (Nakai et al., 1996), was little-
affected by the E4032A mutation. Therefore, Ca2 release
from RyR1 does not appear to play a major role in the
retrograde signal from RyR1 to 1S.
MATERIALS AND METHODS
Mutagenesis
The mammalian expression plasmid (E4032A-RyR1-pCDNA3), in which
the point mutation E4032A was introduced into RyR1, was constructed by
the overlap extension method (Ho et al., 1989) using polymerase chain
reaction (PCR). The “outer” two oligonucleotides used were forward,
5-GTGTTCAACAGCCTCACCGA-3; and reverse, 5-GAACTGCT-
TCTGGCTGTCCA-3. The oligonucleotides for the E4032A mutation
were forward, 5-GTCCCTACTGGCAGGGAACGTGGT-3; and reverse,
5-CCACGTTCCCTGCCAGTAGGGACA-3. The sequence of the PCR
product was confirmed by DNA sequencing. The XhoI (12018)-StuI
(12224) fragment was removed from the PCR product and was used to
replace the corresponding wild-type region in the XhoI (12018)-XbaI (3
end) fragment of the RyR1 cDNA in pBluescript. The XhoI (12018)-XbaI
(3 end) fragment containing the E4032A mutation was subcloned into the
RyR1 cDNA in pHSVprPUC vector lacking the XhoI (6466)-XhoI (12018)
fragment, which was subsequently added back to form the full-length
E4032A-RyR1 cDNA. The full-length E4032A-RyR1 cDNA (HindIII-
XbaI) was transferred from pHSVprPUC to pCDNA3 to form the expres-
sion plasmid E4032A-RyR1-pCDNA3 .
Single channel analysis
For the measurements of single RyR channels, RyR cDNAs were ex-
pressed in 1B5 myotubes. The 1B5 cells were cultured in DMEM (Dul-
becco’s modified Eagle’s medium, GIBCO/BRL, Germantown, MD) con-
taining 20% fetal bovine serum in collagen-coated 100 mm polystyrene
plates (Protasi et al., 1998; Moore et al., 1998). When the cells attained
30–50% confluence, they were differentiated within a 20% CO2 incubator
at 37°C for 5 days in 5% heat-inactivated-horse serum in DMEM before
infection with RyR-cDNA containing viruses (Wang et al., 2000). Briefly,
cDNA encoding either wild-type RyR1 or E4032A-RyR1 was added to
differentiated 1B5 myotubes at a concentration of 3–5  105 infectious
units (IU)/ml. Cells were harvested and sarcoplasmic reticulum (SR) pre-
pared 48 h after infection.
Crude membrane homogenates from 1B5 myotubes expressing
E4032A-RyR1 were prepared as described previously (Moore et al., 1998)
and subsequently loaded onto a sucrose gradient consisting of layers of
10%, 27%, and 45% w/w sucrose, 10 mM HEPES pH 7.4. After sedimen-
tation of the crude membranes on this gradient at 40,000  g for 1 h at 4°C,
the 27–45% interface containing heavy SR membranes was isolated and
diluted in 10 mM HEPES, pH 7.4 and subsequently pelleted at 110,000 
g for 1 h. The pellet was resuspended in 10% sucrose, 10 mM HEPES, pH
7.4, divided into small aliquots and either used immediately or stored at
80°C for no more than two weeks.
Heavy SR membrane vesicles were fused with an artificial bilayer lipid
membrane (BLM) composed of a 5:2 mixture of natural phosphatidyleth-
anolamine and phosphatidylcholine (PE/PC 5:2 mixture) at 50 mg/ml in
decane. The BLM was formed across a 200- to 250-m hole in a polysty-
rene cup separating two chambers (cis and trans), each 0.7 ml. Vesicles
(0.1–5 g protein) were added to the cis chamber in the presence of 200
M Ca2. The cis and trans chambers contained 500 mM CsCl, 20 mM
HEPES (pH 7.4), and 100 mM CsCl, 20 mM HEPES (pH 7.4), respec-
tively. After fusion, 300 M EGTA was added to the cis chamber to
prevent additional fusion events. The cis chamber was then perfused with
a solution composed of 500 mM CsCl, 20 mM HEPES, pH 7.4 (asymmet-
rical CsCl 5:1 cis/trans). A patch-clamp amplifier (Dagan, model 3900)
was used to measure currents through a single channel. The data were
filtered at 1 kHz (low-pass, 8-pole Bessel filter, Warner Instrument Corp.,
Hamden, CT) before acquisition at 10 kHz by a DigiData 1200A (Axon
Instruments, Foster City, CA). Experimental reagents were added to the cis
chamber and stirred for 30 s. Subsequent channel-gating behavior was
recorded for 1–20 min using Axoscope 8.0 (Axon Instruments). Single-
channel data from BLM experiments were analyzed using pCLAMP6
(Axon Instruments), and Fig. 1 was prepared using Origin 4.0 (Microcal,
Northampton, MA).
Expression of cDNA in primary myotubes
Primary cultures of dyspedic mouse myotubes were obtained as previously
described (Nakai et al., 1996; Rando and Blau, 1994). At 6–7 days after
initial plating, a single nucleus of each cell was microinjected with 0.3
g/l of either E4032A-RyR1-pCDNA3 or RyR1-pCI-neo (Nakai et al.,
FIGURE 1 E4032A-RyR1 reconstituted into bilayer lipid membranes
after expression in 1B5 myotubes is negligibly activated by physiological
and pharmacological agonists of RyR1. Top panel: of 100 fusion events
for E4032A-RyR1, 25 contained rare and very brief transitions to the open
state that prevented calculation of Po in the presence of cis 100 M Ca2,
2 mM ATP, and 2 mM caffeine (Po  0.0001, n 	 25). The remainder
produced an offset current (indicative of SR membrane fusion) but no
gating events attributable to RyR. Middle panel: increasing cis Ca2 to 1
mM resulted in a measurable elevation in Po (Po 	 0.002 
 0.001, n 	 6).
Bottom panel: in the presence of 2 mM Ca2, the average Po determined
for E4032A-RyR1 was 0.005 
 0.0006 (n 	 10).
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1998) and 0.2 g/l of an expression plasmid (Jurman et al., 1994) for the
surface antigen CD8. Approximately 48 h later, the medium was removed
from injected myotubes and replaced with external recording solution (see
below) containing beads coated with CD8 antibody (Dynabeads M-450,
Dynal AS, Oslo, Norway), which allowed identification of cells that were
expressing CD8, and thus candidates to express the RyR construct of
interest. Alternatively, the RyR cDNA was injected together with 0.04
g/l cDNA for green fluorescent protein (Grabner et al., 1998). After
48 h, the GFP-positive myotubes, while bathed in DMEM, were tested for
the ability to contract in response to stimulation (100 V, 10 ms) via an
extracellular pipette that was filled 150 mM NaCl and positioned with its
tip near (30 m) the cell.
Measurement of Ca2 currents and
Ca2 transients
Ca2 currents and Ca2 transients were recorded simultaneously (Garcı´a et
al., 1994) using a combination of the whole-cell patch technique and
fluorometric monitoring of myoplasmic Ca2 by means of Fluo-3, which
was included in the “internal solution” (composition given below). Patch
pipettes were pulled from borosilicate glass and had resistances of 1.6 to
2.0 M when filled with internal solution. After a seal was obtained
between the patch pipette and a myotube, the cell was washed to remove
any Fluo-3 that might have leaked into the bath from the pipette. A period
of 5 min was allowed after breaking into whole-cell mode so that Fluo-3
could diffuse throughout the myotube. Cells were held at 80 mV and
control (linear capacitive and leak) currents were measured by steps to
110 mV. Cell capacitance was determined by integration of the control
current and used to normalize Ca2 currents (pA/pF). Additionally, the
average of 10 control currents was digitally scaled and subtracted from test
currents to correct for linear components of leakage and capacitative
current. The voltage protocol for test currents consisted of a 1-s prepulse to
30 or 20 mV to inactivate T-type current, followed by a 50-ms
repolarization to 50 mV, followed by a 200-ms step to the test potential,
a 125-ms step to 50 mV, and finally a return to the holding potential.
For the measurement of fluorescence, a rectangular slit and iris dia-
phragm were adjusted so that the illumination from a 75 W xenon bulb was
restricted to a segment of the myotube that avoided both surrounding cells
and the patch pipette. To prevent prolonged exposure of cells to this
illumination, a digitally controlled shutter was opened 1 s before the test
step and closed immediately after the return to the holding potential.
Fluorescence emission was recorded with standard filters for fluorescein
(excitation centered at 470 nm with half-height width of 20 nm, dichroic
510 nm long pass, emission 520 nm long pass) and a photometer system
(Biomedical Instrumentation Group, University of Pennsylvania). Data
were acquired and analyzed with a PDP-11/73 computer system (INDEC,
Sunnyvale, CA).
For the measurement of changes of myoplasmic calcium in response to
application of caffeine, intact myotubes were rinsed with serum-free
DMEM and then incubated for 1 h at 37°C in serum-free DMEM con-
taining 5.5 M Fluo-3 AM (Molecular Probes, Eugene, OR). After load-
ing, the cells were returned to normal culture medium (DMEM with serum)
and placed in the incubator for a minimum of 30 min before experimen-
tation. Fluorescence responses were recorded with pClamp 8.0 (Axon
Instruments).
Solutions
The internal solution contained (in mM) 145 cesium glutamate, 8 MgATP
(1 mM free Mg2), 2 CsCl, 10 HEPES, 10 EGTA, and 0.5 K5 Fluo-3
(Molecular Probes). The external solution used for measuring Ca2 cur-
rents and Ca2 transients contained (in mM) 145 TEACl, 10 HEPES, 10
CaCl2, and 0.003 TTX. To test the effects of Cd2 plus La3 (0.5 and 0.1
mM, respectively) or of caffeine (1 or 10 mM), individual, patch-clamped
myotubes were analyzed before and after the external solution was re-
placed with external solution containing the indicated substances. The
effects of caffeine were tested on only a single myotube per culture dish.
Analysis
Because intracellular Ca2 release was reduced severalfold for E4032A-
RyR1, we characterized release in terms of F, the change in fluorescence
from baseline (F), rather than as F/F, because F was quite stable during
the course of an experiment, whereas the baseline fluorescence gradually
increased, apparently due to incomplete removal of myoplasmic Ca2.
Additionally, F was measured 40 ms after the onset of depolarization to
help reduce the contribution of the entry of extracellular Ca2 due to Ca2
current. Values of F were plotted versus test potential (V) and fitted
according to the equation:
F Fmax/1 exp V V1/2/kF (1)
where Fmax is the maximum fluorescence change, V1/2 is the potential
eliciting a half-maximal F, and kF is a parameter related to the steepness
of voltage-dependence. In addition to measuring amplitude, we visually
fitted a straight line to the onset of the transient to determine the initial
slope (in F/ms).
Data are reported as mean 
 SEM and exclude cells that had peak Ca2
currents 1 pA/pF and transients indistinguishable from baseline noise, on
the assumption that these cells were likely expressing CD8, but not the
RyR construct. Statistical comparisons were made with Student’s t-test.
RESULTS
To analyze the effects of the E4032A mutation at the single
channel-level, wild-type and mutant RyR1 were produced
by transduction of myotubes obtained by differentiation of
1B5 cells, an immortal myogenic cell line lacking a func-
tional copy of the native RyR1 gene. As observed after
reconstitution of native RyR1 from rabbit skeletal muscle
junctional SR, wild-type RyR1 channels isolated from
transduced 1B5 myotubes have been shown to exhibit large-
conductance events (400 pS for 100 mM Cs) with rapid,
full-conductance gating transitions that are sensitive to
modulation by Ca2, Mg2, caffeine, adenine nucleotides,
ryanodine, and ruthenium red (Moore et al., 1998; Wang et
al., 2000). Consistent with this previous work, we found that
reconstituted wild-type RyR1 was strongly activated by
exposure on the cis side to 100 M Ca2 (Po ranging from
0.64 to 0.95, averaging 0.88 
 0.08, n 	 9), whereas the
reconstituted E4032A-RyR1 was not (Po too low to be
measured, data not shown). In fact, several attempts to
activate E4032A-RyR1 by cis exposure to a combination of
activators (100 M free Ca2, 2 mM ATP, and 2 mM
caffeine) yielded negligible gating activity (Fig. 1, top
panel, Po  0.0001). Thus, the E4032A mutation severely
impairs activation by Ca2 compared to wild-type RyR1
isolated from 1B5 myotubes and measured under similar
conditions (Wang et al., 2000). We also examined the
behavior of E4032A-RyR1 in the presence of mM Ca2 in
the cis solution since mM Ca2 was found to cause mea-
surable activation (Po of 0.016) of RyR3 bearing the muta-
tion (E3885A) homologous to that of E4032A-RyR1 (Chen
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et al., 1998). When Ca2 was raised to 1–5 mM, channel
activity of E4032A-RyR1 exhibited only a modest enhance-
ment (not shown), but reached a discernible level when a
combination of strong activators was included in the cis
chamber (Fig. 1, middle and bottom panels). However,
unlike wild-type RyR1 and E3885A-RyR3, the gating ac-
tivity of E4032A-RyR1 remained extremely low (typically
Po  0.005) under all the conditions tested. The inability to
cause an appreciable Po for E4032A-RyR1 makes it diffi-
cult to quantify the effects of the mutation on Ca2 activa-
tion. However, comparison of Po for wild-type RyR1 in 100
M Ca2 (0.88) with the maximal Po that we observed for
E4032A-RyR1 under any condition (0.005 in 2 mM Ca2,
2 mM ATP and 2 mM caffeine), suggests a 100-fold
decrement in the maximal ability of Ca2 to cause acti-
vation, alone or together with other strongly activating
ligands.
To determine whether the E4032A mutation affects the
ability of RyR1 to mediate EC coupling, the mutant protein
was expressed in dyspedic myotubes, which lack endoge-
nous RyR1 (Takeshima et al., 1994), but do express other
key proteins of the triad junction, including 1S (Buck et al.,
1997). When cells expressing E4032A-RyR1 were focally
stimulated (100 V, 10 ms), no evoked contractions were
observed in the 28 cells tested, whereas all 13 cells express-
ing wild-type RyR1 contracted when stimulated. Thus, the
E4032A mutation impairs the ability of RyR1 to mediate
EC coupling. To obtain a more quantitative estimate of this
impairment, we used the whole-cell variant of the patch
clamp technique together with Fluo-3 to measure Ca2
transients. As shown in Fig. 2 a, depolarization caused Ca2
release via E4032A-RyR1, but this was about fivefold
smaller than for RyR1. Specifically, at 40 mV, F values
for E4032A-RyR1-expressing cells was 35.31 
 4.47 (n 	
28) compared with 181.67 
 20.36 (n 	 27) for RyR1
(significantly different, p  0.001). The rate of fluores-
cence release (F/ms) at 40 mV showed a similar reduc-
tion from 7.84
 1.18 (n	 27) for RyR1 to 1.54
 0.20 for
E4032A-RyR1 (n 	 28). No transients were observed in
dyspedic myotubes (n 	 10). The amplitude of Ca2 tran-
sients for E4032A-RyR1 showed a sigmoidal dependence
on voltage similar to that of RyR1 (Fig. 2 b). Under the
assumption that SR Ca2 content was similar in myotubes
expressing wild-type and mutant RyR1, the reduced ampli-
tude of Ca2 transients for E4032A-RyR1 implies that the
mutant RyRs are activated to a lesser extent during EC
coupling.
The results above show that although E4032A-RyR1
does not release enough Ca2 to mediate electrically evoked
contractions, it does support depolarization-evoked Ca2
transients of small amplitude. To determine whether Ca2
release via E4032A-RyR1 reflects skeletal-type EC cou-
pling, Ca2 transients were measured in individual cells for
a test pulse to 40 mV immediately before and after addi-
tion of 0.5 mM Cd2 and 0.1 mM La3 to the bathing
medium. This addition effectively blocked Ca2 current
(Fig. 3 a, lower sets of traces), without altering the ampli-
tude of the Ca2 transients for either RyR1 or E4032A-
RyR1 (Fig. 3 a, upper set of traces; Fig. 3 b). These results,
together with the sigmoidal voltage-dependence of the tran-
sients (Fig. 2 b) imply that E4032A-RyR1 is able to mediate
skeletal-type EC coupling.
In addition to receiving the EC coupling signal from 1S,
RyR1 transmits a retrograde signal that acts to increase the
magnitude of the L-type Ca2 current produced by 1S
(Nakai et al., 1996). Fig. 4 illustrates representative L-type
Ca2 currents (a) and average peak current versus voltage
relationships (b) for dyspedic myotubes and myotubes
expressing RyR1 or E4032A-RyR1. Although having
similar voltage dependence, the peak currents differed
considerably in magnitude for the three groups. At 30
mV, peak current density for E4032A-RyR1 (6.53 

0.54 pA/pF, n 	 28) was much larger (p  0.001) than
for dyspedic myotubes (1.35 
 0.30 pA/pF, n 	 10),
but not quite as large (p  0.005) as for wild-type RyR1
(10.11 
 0.79 pA/pF, n 	 35).
Because caffeine is a potentiator of Ca2-induced Ca2
release (Meissner et al., 1997), it was of interest to deter-
mine whether caffeine affected depolarization-evoked Ca2
release via E4032A-RyR1. The application of 10 mM
caffeine to myotubes at the holding potential caused a
large release of Ca2 in RyR1-expressing myotubes
(113.36 
 28.76 F; n 	 4), but caused no release in
E4032A-RyR1-expressing myotubes (n 	 7; Fig. 5 a).
This difference provides additional support for the idea
that the E4032A mutation impairs Ca2 activation. De-
spite having little effect on E4032A-RyR1 at the holding
potential, 10 mM caffeine did cause a large increase in
the amplitude of the depolarization-induced Ca2 tran-
FIGURE 2 The mutation E4032A in RyR1 reduces depolarization-in-
duced Ca2 release. (a) Representative Ca2 transients (F) from control
dyspedic myotubes and dyspedic myotubes expressing E4032A-RyR1 or
RyR1. The transients were elicited by a 200-ms depolarization to 40 mV
(black bar). (b) Voltage dependence of the Ca2-induced increase of
fluorescence measured 40 ms after the onset of depolarization for E4032A-
RyR1 (n 	 28) and RyR1 (n 	 27). Ca2 transients were absent in
dyspedic myotubes (n 	 10; not shown). The smooth curves represent
best-fits of the Boltzmann expression (Eq. 1) with values of k 	 10.66 and
8.13 mV, and V1/2 	 18.34 and 10.36 mV, for E4032A-RyR1 and wild-
type RyR1, respectively.
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sient (Fig. 5 b), which on average was about fourfold (F
increased from 20.6 
 3.0 to 78.2 
 12.39, n 	 10, p 
0.001). In the presence of 10 mM caffeine, the F versus
voltage relationship for E4032A-RyR1 remained sigmoi-
dal, although steeper and somewhat left-shifted com-
pared to control (Fig. 5 c). Additionally, caffeine in-
creased the initial rate of rise of the Ca2 transient in
E4032A-RyR1-expressing cells from 0.81 
 0.13 to
3.25 
 0.58 F/ms (n 	 10; p  0.001).
In addition to increasing the amplitude of the Ca2 tran-
sient in myotubes expressing E4032A-RyR1, the applica-
tion of 10 mM caffeine also caused the half-rise time for
activation of Ca2 current to decrease from 23.4 
 2.2 ms
to 11.6
 0.6 ms (n	 10, p 0.001). The effect of caffeine
on the rate of activation of Ca2 current appeared to be
unrelated to its effect on Ca2 release. First, the half-rise
time for activation of Ca2 current in the absence of caf-
feine was similar (p  0.15) in cells expressing wild-type
RyR1 (18.1 
 1.3 ms, n 	 35) to that in cells expressing
E4032A-RyR1 (21.2
 1.7 ms, n	 28), despite the fact that
Ca2 release flux was severalfold lower for E4032A-RyR1
(see above). Second, 10 mM caffeine caused half-rise times
for Ca2 current in four cells expressing wild-type RyR1 to
decrease from 18.0 
 2.0 ms to 10.3 
 0.3 ms, despite
causing a reduction in the amount of calcium released
(maximum F fell from 355.3 
 60.5 to 139.3 
 52.9,
presumably because the caffeine caused a loss of Ca2 from
the SR).
DISCUSSION
In this paper we have characterized the consequences of the
mutation E4032A on the function of RyR1. Expression in
1B5 dyspedic myotubes followed by reconstitution into
planar lipid bilayers demonstrated that E4032A-RyR1 is not
appreciably activated by Ca2, even when the additional
strong activators caffeine and ATP are also present. Expres-
sion in primary dyspedic myotubes followed by whole-cell
measurements showed that the E4032A mutation reduced
depolarization-induced Ca2 release about fivefold as com-
pared with wild-type RyR1, and as a result impaired the
ability of RyR1 to mediate EC coupling. This reduction
implies that the E4032A mutation impairs activation of
Ca2 release in response to depolarization (under the as-
sumption that the mutation did not cause a reduction in SR
Ca2 content). The Ca2 release that did occur for E4032A-
RyR1 appeared to reflect skeletal-type EC coupling because
its amplitude showed a sigmoidal voltage-dependence and
because it persisted after the addition of extracellular Cd2
and La3 to block Ca2 influx. In addition to being able to
mediate EC coupling (at a reduced level), E4032A-RyR1
was also able to cause retrograde enhancement of L-type
Ca2 current via 1S. Compared to control dyspedic cells,
the L-current density was about fivefold larger for E4032A-
RyR1-expressing myotubes, a retrograde enhancement
somewhat smaller than that found for wild-type RyR1
(7.5-fold).
The results reported here raise the question of whether
there is a direct relationship between activation of RyR1 by
1S (in response to depolarization) and the activation of
RyR1 by Ca2. Fig. 6 illustrates two extreme possibilities
FIGURE 4 The E4032A mutation of RyR1 slightly impairs retrograde
signaling. (a) Representative peak Ca2 currents (at 20 mV) from con-
trol, E4032A-RyR1-expressing and RyR1-expressing dyspedic myotubes.
(b) Average peak current versus voltage relationships for dyspedic myo-
tubes (gray circles; n 	 10) and dyspedic myotubes expressing E4032A-
RyR1 (white circles; n 	 28) or RyR1 (black circles; n 	 35).
FIGURE 3 E4032A-RyR1 supports skeletal-type EC coupling. (a) Rep-
resentative Ca2 transients and Ca2 currents recorded at 40 mV before
(black) and after (gray) application of Cd2 and La3 to block Ca2 entry.
The transients before and after the block of Ca2 current almost completely
overlapped, indicating that, like RyR1, E4032A-RyR1 supports skeletal-
type EC coupling. (b) Average Ca2 transient amplitude at 40 mV was
not significantly different before (black) and after (gray) application of
Cd2 and La3 for either RyR1 (n 	 7; p  0.5) or E4032A-RyR1 (n 	
7; p  0.5).
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for the relationship between the two modes of activation. In
scheme 1 the two modes of activation are completely inde-
pendent, whereas in scheme 2 the only function of 1S is to
lower the threshold for activation by Ca2 such that resting
Ca2 is sufficient to cause activation. Scheme 2 can be
viewed as the converse of the proposal that 1S functions to
raise the threshold for the inhibition of RyR1 by Mg2
(Lamb and Stephenson, 1991, 1994). If scheme 1 were
correct, it might be possible to abolish activation by Ca2
without any effect on depolarization-induced Ca2 release.
If scheme 2 were correct, then eliminating activation by
Ca2 would also abolish activation by 1S. An argument
against scheme 2 is that the E4032A mutation does not
abolish depolarization-induced Ca2 release, although one
could argue that E4032A-RyR1 has sufficient residual Ca2
sensitivity to support a reduced level of depolarization-
induced release. However, the effect of the mutation on
depolarization-induced release is trivial compared to its
effect on Ca2 activation. Specifically, the bilayer experi-
ments indicate that the E4032A mutation depressed activa-
tion by Ca2 by 100-fold, whereas the reduction in de-
polarization-induced release was only 5-fold. Thus, it seems
unlikely that Ca2 activation plays an obligatory role in
depolarization-induced release.
Because the E4032A mutation affects activation of RyR1
both by depolarization (as shown in myotubes) and by Ca2
(as shown in bilayers), it is possible that the two activation
pathways interact with one another in intact cells. Such an
interaction could take place either in the same RyR mole-
cule or between different RyR molecules. In the latter case,
for example, the Ca2 initially released from some RyRs in
response to depolarization could induce release from adja-
cent RyRs via Ca2 activation (Rios and Pizarro, 1991;
Schneider, 1994). Put another way, Ca2 	 VGCR 
CICR, where Ca2 is the total amount of Ca2 released by
depolarization, part of which is from RyRs activated di-
rectly by DHPRs (VGCR) and part from RyRs secondarily
activated by Ca2 (Rios and Pizarro, 1991; Schneider,
1994). Accordingly, the interpretation of the fivefold reduc-
tion in depolarization-induced Ca2 release in myotubes
expressing E4032A-RyR1 depends on knowing whether the
mutation affects only CICR. If this were the case, one would
conclude that CICR is responsible for the bulk of total Ca2
release and that VGCR contributes only a relatively small
fraction (20%). Alternatively, it is common that synergis-
tic interactions occur between ligands that activate an allo-
steric protein; that is, activation of a single RyR by depo-
FIGURE 5 Caffeine enhances depolarization-induced Ca2 release for E4032A-RyR1. (a) Caffeine (10 mM) causes Ca2 release from RyR1 expressing
myotubes at the holding potential (80 mV), but not from myotubes expressing E4032A-RyR1. Similar responses were obtained from a total of eight cells
expressing E4032A-RyR1 (F 	 0) and four cells expressing RyR1 (F 	 113.36 
 28.76). Bath perfusion (horizontal bar) was used to introduce 10
mM caffeine, which then remained for the duration of the experiment. (b) Representative Ca2 transients (top) and Ca2 currents (bottom) at 40 mV
before (black) and after (gray) the application of 10 mM caffeine. (c) Voltage dependence of the Ca2 transients measured in E4032A-RyR1-expressing
myotubes before and after application of 10 mM caffeine (n 	 10). The data have been fitted with Eq. 1, as shown by the smooth curve. The values for
k are 9.87 and 5.89 mV and for V1/2 are 27.13 and 21.69 mV before and after caffeine was applied.
FIGURE 6 Two schemes indicating pathways for activation of RyR1
(R), with horizontal arrows indicating reversible binding steps, and vertical
arrows indicating conformational changes that convert RyR1 to the active
state, indicated by the asterisk (). According to scheme 1, depolarization
causes a domain of the 1S (D, possibly the II-III loop) to bind to and
activate RyR1 independently of the activation occurring in response to
Ca2 (C). In scheme 2, the binding of D cannot by itself induce activation,
which requires Ca2. Specifically, the binding of D increases the affinity
of RyR1 for Ca2 so that the threshold for activation is below that of the
resting myoplasmic concentration.
Ca2 Sensing in Skeletal-Type EC Coupling 2433
Biophysical Journal 82(5) 2428–2435
larization would be potentiated by Ca2, and activation of
an RyR by Ca2 would be potentiated by depolarization.
Thus, a mutation that depressed CICR might well be ex-
pected to depress VGCR. However, even if the two activa-
tion pathways were completely independent, there is no
reason why the E4032A mutation could not affect both.
Caffeine is widely thought to act on ryanodine receptors
by reducing the threshold for activation by Ca2 (e.g.,
Meissner et al., 1997). Thus, it is of interest that the appli-
cation of 10 mM caffeine caused an approximately fourfold
augmentation in the depolarization-evoked release of Ca2
by E4032A-RyR1 without having any discernible effect at
the holding potential. This augmentation appears to be dif-
ficult to explain if the only effect of caffeine is on the
Ca2-activation threshold. In bilayers, Ca2 caused mini-
mal activation of E4032A-RyR1, even when 2 mM caffeine
was present (Fig. 1). Thus, rather than simply shifting the
apparent Ca2-activation threshold by enhancing the bind-
ing affinity of the activator site for Ca2, caffeine may have
the more general effect on ryanodine receptors of reducing
the energy of channel activation and shifting the equilibrium
toward the open state.
A limitation in our comparison of the properties of wild-
type RyR1 and E4032A-RyR1 is that we have no indepen-
dent measure of the expression level or junctional targeting
of the mutant protein. However, it seems unlikely that
expression or targeting is significantly altered because
E4032A-RyR1 caused a substantial increase in the ampli-
tude of L-type Ca2 current compared to that in non-
injected dyspedic cells. This result suggests that E4032A-
RyR1 is expressed at a level similar to that of RyR1, and is
like RyR1 in being able to increase the magnitude of current
normalized by the number of 1S subunits in the plasma
membrane (Nakai et al., 1996; Avila et al., 2001). Avila et
al. (2001) also found that retrograde signaling by E4032A-
RyR1 was similar to that of RyR1, although E4032A-RyR1
lacked the ability to cause an up-regulation of the number of
1S subunits in the plasma membrane that occurs on the
time scale of several days. Because E4032A-RyR1 was able
to mediate retrograde enhancement of Ca2 current despite
a greatly reduced orthograde signaling (EC coupling), it
suggests that the two processes are not tightly linked. Fur-
ther support for this idea is that caffeine caused a large
increase in depolarization-induced Ca2 release by
E4032A-RyR1 without much effect on the amplitude of
L-type current (Fig. 5). Thus, it does not seem likely that
Ca2 release is the signal for retrograde enhancement of
L-type current.
The depression of Ca2 activation by the E4032A muta-
tion could mean that the mutation directly affects the Ca2
binding site for activation (Chen et al., 1998; Li and Chen,
2001). An alternative possibility is that the E4032A muta-
tion induces a folding error that impairs channel-opening
conformational changes (Fessenden et al., 2001). According
to this latter interpretation, calcium would be less effective
at overcoming the impairment of channel-opening than
would orthograde activation via the DHPR, and this ortho-
grade activation would be directly potentiated by caffeine.
However, no matter which interpretation is correct, the
essential conclusion from our work is that Ca2 activation
of RyR1 is not essential for the initiation of skeletal-type EC
coupling.
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